Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Gross Profit (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Gross Profit data on record, last reported at $119.8 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 91.84% year-over-year to $119.8 million; the TTM value through Dec 2025 reached $339.4 million, up 130.22%, while the annual FY2025 figure was $339.4 million, 130.22% up from the prior year.
  • Gross Profit reached $119.8 million in Q4 2025 per ARQT's latest filing, up from $90.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $119.8 million in Q4 2025 and bottomed at $456000.0 in Q3 2022.
  • Average Gross Profit over 4 years is $38.3 million, with a median of $28.1 million recorded in 2023.
  • Peak YoY movement for Gross Profit: skyrocketed 6219.74% in 2023, then soared 36.21% in 2024.
  • A 4-year view of Gross Profit shows it stood at $2.5 million in 2022, then surged by 355.57% to $11.3 million in 2023, then skyrocketed by 453.68% to $62.5 million in 2024, then skyrocketed by 91.84% to $119.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $119.8 million in Q4 2025, $90.5 million in Q3 2025, and $74.0 million in Q2 2025.